Hillman Value Fund BMY trades
Mark A. Hillman
Mark A. Hillman Bristol-Myers Squibb Company stake
total: 76
Trades details
- Total transactions:
- 11
- New positions:
- 2
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 5
- Held since:
- 2024 Q2
- Held for:
- 9 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Mark A. Hillman holds 37,500 Bristol-Myers Squibb Company (BMY) shares with a market value of roughly $2.16M accounting for 2.76% of the overall portfolio. To date, the estimated cost basis is nearly $41.7 for "buy" trades and estimated average "sell" price is $57.78. Hillman Value Fund first purchased BMY in 2020 Q1, initially acquiring 46,000 shares. Mark A. Hillman later completely sold out the position and invested in Bristol-Myers Squibb Company again in 2024 Q2. Since the initial investment in Bristol-Myers Squibb Company (BMY), Hillman Value Fund has made 10 more transactions.
When did Mark A. Hillman buy Bristol-Myers Squibb Company (BMY)?
Mark A. Hillman first invested in Bristol-Myers Squibb Company (BMY) in 2020 Q1 at the reported quarter-end price of $55.74 per share.
What's the cost basis of Hillman Value Fund's BMY stake?
The estimated cost basis for Bristol-Myers Squibb Company (BMY) stake is around $41.70 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $41.70
- Weighted AVG sell price:
- $57.78
Mark A. Hillman's historical trades in Bristol-Myers Squibb Company
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
2.76%
|
37,500
|
$57.62
|
$2,160,750
|
-19.18% (-8,900)
|
-0.62%
|
|
2025 Q4
|
2.67%
|
46,400
|
$53.94
|
$2,502,816
|
-25.28% (-15,700)
|
-0.81%
|
|
2025 Q3
|
2.67%
|
62,100
|
$45.10
|
$2,800,710
|
-4.90% (-3,200)
|
-0.12%
|
|
2025 Q2
|
2.55%
|
65,300
|
$46.29
|
$3,022,737
|
+9.38% (+5,600)
|
+0.22%
|
|
2025 Q1
|
2.56%
|
59,700
|
$60.99
|
$3,641,103
|
-45.08% (-49,000)
|
-1.42%
|
|
2024 Q4
|
2.91%
|
108,700
|
$56.56
|
$6,148,072
|
-29.42% (-45,300)
|
-1.12%
|
|
2024 Q2
|
2.82%
|
154,000
|
$41.53
|
$6,395,620
|
new
|
+2.82%
|
|
2022 Q2
|
0.00%
|
0
|
$73.03
|
|
-100% (-93,000)
|
-2.76%
|
|
2021 Q3
|
2.55%
|
93,000
|
$59.17
|
$5,502,810
|
+19.23% (+15,000)
|
+0.41%
|
|
2021 Q1
|
2.85%
|
78,000
|
$63.13
|
$4,924,140
|
+69.57% (+32,000)
|
+1.17%
|
|
2020 Q1
|
3.58%
|
$55.74
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.